ESC 2017
Routine use of supplemental oxygen does not reduce one-year all-cause mortality versus ambient air
News
Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients.
Drugs in the Pipeline
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Drugs in the Pipeline, News
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.
Drugs in the Pipeline, News
The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Drugs in the Pipeline
Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.
News
Currently, there are no approved treatments for COVID-19, however, several investigational therapies are in the works.
Drugs in the Pipeline
The placebo-controlled ACTT 3 trial will evaluate the efficacy and safety of remdesivir in combination with interferon beta-1a in more than 1000 hospitalized COVID-19 patients.
ACAAI 2020
Investigators evaluated the relationship between atopic dermatitis and frequency of severity markers in patients hospitalized with COVID-19.
Drugs in the Pipeline
Both randomized, placebo-controlled trials are expected to enroll approximately 1000 hospitalized patients.